Johnson & Johnson $JNJ Shares Sold by Carlton Hofferkamp & Jenks Wealth Management LLC

Carlton Hofferkamp & Jenks Wealth Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,120 shares of the company’s stock after selling 872 shares during the period. Johnson & Johnson comprises 0.9% of Carlton Hofferkamp & Jenks Wealth Management LLC’s investment portfolio, making the stock its 27th biggest holding. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,529,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter valued at about $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson during the first quarter worth about $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of analyst reports. Argus set a $210.00 price target on Johnson & Johnson in a report on Wednesday, October 15th. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 15th. HSBC increased their target price on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Finally, Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Stock Down 1.1%

JNJ opened at $190.38 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The business has a 50 day moving average price of $182.26 and a 200 day moving average price of $166.13. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.07. The firm has a market cap of $458.69 billion, a P/E ratio of 18.38, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.